New Guideline Developed for Management of High Blood Pressure
By Elana Gotkine HealthDay Reporter
TUESDAY, Aug. 26, 2025 -- In a new 2025 joint guideline issued by the American Heart Association and the American College of Cardiology, published online Aug. 14 in Circulation, updated recommendations are presented for the management of elevated blood pressure and hypertension.
Daniel W. Jones, M.D., from the University of Mississippi Medical Center in Jackson, and colleagues conducted a comprehensive literature review to update the 2017 guidelines for the management of high blood pressure in adults.
The authors note that the overarching blood pressure treatment goal is <130/80 mm Hg for all adults. Screening should be implemented for all adults in the community, and guideline-based recommendations should be implemented to improve blood pressure control. Lifestyle changes are strongly recommended for all adults to prevent or treat elevated blood pressure and hypertension, including maintaining or achieving a healthy weight, following a heart-healthy eating pattern, reducing sodium intake, increasing dietary potassium intake, adopting a moderate physical activity program, managing stress, and reducing or eliminating alcohol.
For all adults with an average blood pressure ≥140/90 mm Hg and/or for selected adults with average blood pressure ≥130/80 mm Hg, including those at risk according to the American Heart Association PREVENT risk calculator, initiation of medication therapy is recommended in addition to lifestyle interventions.
The authors of the guideline also recommend use of the ratio of urine albumin to creatinine for all patients with high blood pressure and expand indications for use of the plasma aldosterone-to-renin ratio test as a screening tool for primary aldosteronism in more patients.
"It is important for people to be aware of the recommended blood pressure goals and understand how healthy lifestyle behaviors and appropriate medication use can help them achieve and maintain optimal blood pressure," Jones said in a statement.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2025
Read this next
Unfavorable Mental Health Outcomes Reported With THC Product Use
TUESDAY, Aug. 26, 2025 -- High-concentration delta-9-tetrahydrocannabinol (THC) cannabis products are associated with unfavorable mental health outcomes, according to a review...
Many Women Have Preexisting Modifiable Risk Factors for Birth Defects
TUESDAY, Aug. 26, 2025 -- About two-thirds of reproductive-aged women in the United States have preexisting modifiable risk factors for birth defects, according to a study...
Benefits of Long-Term Routine Lab Drug Toxicity Monitoring Unclear in RA
TUESDAY, Aug. 26, 2025 -- For patients with rheumatoid arthritis (RA) using disease-modifying antirheumatic drugs (DMARDs), long-term routine laboratory toxicity monitoring...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.